[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR080757A1 - Morfolinilquinazolinas, procesos de obtencion, intermediarios, usos y composiciones farmaceuticas. - Google Patents

Morfolinilquinazolinas, procesos de obtencion, intermediarios, usos y composiciones farmaceuticas.

Info

Publication number
AR080757A1
AR080757A1 ARP110100836A AR080757A1 AR 080757 A1 AR080757 A1 AR 080757A1 AR P110100836 A ARP110100836 A AR P110100836A AR 080757 A1 AR080757 A1 AR 080757A1
Authority
AR
Argentina
Prior art keywords
alk
nyy
het2
hal
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
Werner Mederski
Thomas Fuchss
Frank Zenke
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR080757A1 publication Critical patent/AR080757A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a compuestos de las formulas (1), (2) y (3). Los compuestos de la formula (1) se pueden usar para la inhibicion de las serina-treonina-proteína quinasas, así como para la sensibilizacion de células cancerosas a los agentes anticáncer y/o radiacion ionizante. También es objeto de la solicitud el uso de los compuestos de la formula (1) en la prevencion, la terapia o el control del curso de cáncer, tumores, metástasis o trastornos de la angiogénesis, en combinacion con radioterapia y/o un agente anticáncer. La solicitud también se refiere a un procedimiento para la preparacion de los compuestos de la formula (1) por reaccion de los compuestos de las formulas (2) y (3) y eventualmente conversion de una base o un ácido de los compuestos de la formula (1) en una de sus sales. Reivindicacion 1: Compuestos de la formula (1) en donde R1 es H, Hal, CN, A, OY, NYY o -NH-C(NYY)=NY, R2 es H, Cyc, Ar, Het1 o Het2, R3 es Y, OH u OA, R4 es H o Hal, Y es H, A o Alk-OA, W1, W2 es, de modo independiente entre sí, CHR3 o NH, W1-W2 también son juntos CH=CH, L es enlace simple, -CYR3-, -CO-, -CO-NY-, -NY-CO-, -NY-CO-NY-, -NY-SO2-, -C(=NR3)-, -C(=N-CN)-, -Alk-, -Alk-NY-, -Alk-CO-, -Alk-CO-NY-, -AIkO-, -Alk-OAIk-, -Alk-C(Y)(OY)-, -C(Y)(CN)-, -C(Y)(Het1)-, -C(R3)(Het1)-, -C(Y)(Het1)-NY-, -C(Y)(Het2)-, -C(Y)(OY)-, -C(Y)(OCOOY)-, -C(Y)(NYY)-, -C(Y)(NY-COY)-, -C(Y)(NY-CO-NYY)-, -C(Y)(Oalk-CN)-, -C(Y) (Oalk-Het2)-, -C(Y)(Oalk-NYY)-, -C(Y)(OAlk-CO-NYY)-, -C(Y)(OY)-Alk-, -C(Y)(OCO-NYY)-, -C(Y)(OCO-NY-Alk-COOY)- o -C(Y)(OY)-Het1-Alk-OCO-NY-, A es alquilo no ramificado o ramificado C1-10, en donde, de modo independiente entre sí, 1-7 átomos de H pueden estar reemplazados por Hal, Alk es alquileno C1-6, en donde, de modo independiente entre si, 1-4 átomos de H pueden estar reemplazados por Hal y/o CN, Cyc es alquilo cíclico C3-7, en donde, de modo independiente entre sí, 1-4 átomos de H pueden estar reemplazados por A, Hal y/u OY, Ar es fenilo, naftilo o bifenilo no sustituido o mono-, di- o trisustituido con Y, OY, Hal, CN, COOY, -Alk-OY, NYY, -NY-COY, SiY3, Cyc y/o fenilo, Het1 es heteroarilo mono- o bicíclico C2-9 y 1-4 átomos de N, O y/o S, que no está sustituido o que puede estar mono-, di- o trisustituido con Y, OY, Hal, CN, COOY, -Alk-OY, NYY, -NY-COY, -Alk-Het2, -Alk-OCO-Het 2, -Alk-OCO-NY-Het2, -NY-CO-Het2, -NY-CO-Alk-Het2, S1Y3, Cyc y/o fenilo, en donde queda excluido el piridilmetoxi cuando R1 es NYY, Het2 es un heterociclo saturado monocíclico C2-7 y 1-4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar monosustituido con R3 y/o COY, Hal es F, CI, Br o I, y n es 1, 2, 3 o 4, y/o sus sales, tautomeros y/o estereoisomeros fisiologicamente inocuos, incluyendo sus mezclas en todas las proporciones.
ARP110100836 2010-03-16 2011-03-16 Morfolinilquinazolinas, procesos de obtencion, intermediarios, usos y composiciones farmaceuticas. AR080757A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010011493 2010-03-16

Publications (1)

Publication Number Publication Date
AR080757A1 true AR080757A1 (es) 2012-05-09

Family

ID=43828057

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100836 AR080757A1 (es) 2010-03-16 2011-03-16 Morfolinilquinazolinas, procesos de obtencion, intermediarios, usos y composiciones farmaceuticas.

Country Status (16)

Country Link
US (1) US9126952B2 (es)
EP (1) EP2547664B1 (es)
JP (1) JP2013522249A (es)
KR (1) KR20130017086A (es)
CN (1) CN102803227B (es)
AR (1) AR080757A1 (es)
AU (1) AU2011229542A1 (es)
BR (1) BR112012022868A2 (es)
CA (1) CA2793299A1 (es)
EA (1) EA201201289A1 (es)
ES (1) ES2586227T3 (es)
IL (1) IL221901A (es)
MX (1) MX2012010557A (es)
SG (1) SG183855A1 (es)
WO (1) WO2011113512A1 (es)
ZA (1) ZA201207727B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118830A1 (de) * 2011-11-18 2013-05-23 Merck Patent Gmbh Morpholinylbenzotriazine
CN106986863B (zh) 2012-04-24 2019-12-31 沃泰克斯药物股份有限公司 Dna-pk抑制剂
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CA2926328C (en) * 2013-10-10 2022-11-29 Araxes Pharma Llc Substituted quinazolinyl and quinolinyl derivatives and pharmaceutical compositions thereof useful as inhibitors of kras g12c
HUE041877T2 (hu) 2013-10-17 2019-06-28 Vertex Pharma (S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
KR20240044525A (ko) * 2015-04-02 2024-04-04 메르크 파텐트 게엠베하 이미다졸로닐 퀴놀린 및 atm 키나아제 저해제로서의 이의 용도
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3364977A4 (en) 2015-10-19 2019-09-04 Araxes Pharma LLC PROCESS FOR SCREENING INHIBITORS OF RAS
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
MX2019003317A (es) 2016-09-27 2019-08-05 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
JP2019534260A (ja) 2016-10-07 2019-11-28 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤としての複素環式化合物およびその使用方法
WO2018140600A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused hetero-hetero bicyclic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras
EP3630746A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
AU2018357933B2 (en) * 2017-10-31 2019-11-21 Southern Research Institute Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors
JP2021532157A (ja) 2018-08-01 2021-11-25 アラクセス ファーマ エルエルシー がんを処置するための複素環式スピロ化合物およびその使用方法
US20220073475A1 (en) 2019-01-17 2022-03-10 Universite De Lille 5-membered heteroaryl compounds containing a hydroxamate moiety and their use
CN111909144A (zh) * 2019-05-10 2020-11-10 山东轩竹医药科技有限公司 喹唑啉类dna-pk抑制剂
TW202208355A (zh) * 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
EP4146220A4 (en) 2020-05-04 2024-05-29 Amgen Inc. HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTORS EXPRESSED ON MYELOID CELL 2 AGONISTS AND METHODS OF USE

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK400992A3 (en) 1990-11-06 1995-08-09 Pfizer Quinazolines derivatives for enhancing antitumor activity
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODY FOR INCREASING IRRADIATION IN CANCER THERAPY
WO2002020500A2 (en) * 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
DE60237145D1 (de) * 2001-02-21 2010-09-09 Mitsubishi Tanabe Pharma Corp Chinazolinderivate
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
ES2288359B1 (es) 2005-07-08 2009-07-23 Consejo Superior Investigaciones Cientificas Sistema de control coordinado para lineas de extraccion continua de aceite de oliva virgen.
US20080255186A1 (en) * 2005-09-29 2008-10-16 Siegfried Benjamin Christensen Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor
DE102006012251A1 (de) * 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
EP1903038A1 (de) 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren
CA2681572C (en) * 2007-03-23 2014-02-11 Icagen, Inc. Inhibitors of ion channels
UA99141C2 (ru) * 2007-07-20 2012-07-25 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные в качестве ингибиторов киназы
WO2009020140A1 (ja) * 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. アダマンチルウレア誘導体
BRPI0911688A2 (pt) 2008-07-31 2015-07-28 Genentech Inc "compostos de pirimidina, composições e métodos de uso"
EP2516425B1 (en) * 2009-12-23 2015-09-02 Jasco Pharmaceuticals LLC Aminopyrimidine kinase inhibitors

Also Published As

Publication number Publication date
SG183855A1 (en) 2012-10-30
IL221901A (en) 2016-04-21
AU2011229542A1 (en) 2012-11-08
BR112012022868A2 (pt) 2018-06-05
CN102803227A (zh) 2012-11-28
IL221901A0 (en) 2012-12-02
US20130012489A1 (en) 2013-01-10
ZA201207727B (en) 2013-06-26
CN102803227B (zh) 2016-01-20
EP2547664B1 (de) 2016-05-04
ES2586227T3 (es) 2016-10-13
US9126952B2 (en) 2015-09-08
JP2013522249A (ja) 2013-06-13
MX2012010557A (es) 2012-10-05
CA2793299A1 (en) 2011-09-22
KR20130017086A (ko) 2013-02-19
EA201201289A1 (ru) 2013-08-30
WO2011113512A1 (de) 2011-09-22
EP2547664A1 (de) 2013-01-23

Similar Documents

Publication Publication Date Title
AR080757A1 (es) Morfolinilquinazolinas, procesos de obtencion, intermediarios, usos y composiciones farmaceuticas.
AR096235A1 (es) Arilquinazolinas
AR082728A1 (es) Imidazolonilquinolinas utiles para tratar el cancer, composiciones farmaceuticas que las contienen, proceso de sintesis, intermediarios de dicha sintesis y procedimiento para prepararlos
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR119731A1 (es) Inhibidores del inflamasoma nlrp3
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
PE20142360A1 (es) Procesos e intermediarios para preparar un inhibidor de jak
AR104326A1 (es) Compuestos nucleósidos 5-sustituidos
AR057214A1 (es) Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas.
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
UY33961A (es) Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
AR091628A1 (es) 7h-pirrolo[2,3-d]pirimidinas 4-(amino-substituidas) como inhibidores de lrrk2
BR112014011805A2 (pt) morfolinilbenzotriazinas para uso em terapia de câncer
AR072860A1 (es) Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina
CY1120378T1 (el) Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης)
AR073055A1 (es) Derivados biciclicos de triazol
EA201391337A1 (ru) Ингибиторы hsp90
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR092670A1 (es) Derivados de quinazolinona
AR087868A1 (es) Compuestos de triazolopiridina como moduladores de la tirosina quinasa c-met
AR083670A1 (es) DERIVADOS DE 7-([1,2,3]TRIAZOL-4-IL)-PIRROLO[2,3-b]PIRAZINA UTILES COMO INHIBIDORES DE LA PROLIFERACION CELULAR, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y PROCEDIMIENTO PARA PREPARARLOS
BR112013025634A2 (pt) inibidores de hsp90
AR100431A1 (es) Compuestos de pladienolida piridina y métodos de uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure